BURLINGTON, Mass. — PharmaEssentia USA Corporation has appointed Jeffrey R. Williams as an independent director, adding a seasoned global finance and governance leader to its board as the company continues to expand its international presence.
Company officials said Williams brings decades of experience in global finance, corporate governance, and philanthropy, with a career closely tied to East Asia. He has served as an independent director of PharmaEssentia Corporation in Taiwan since May 2024 and is expected to provide strategic insight as PharmaEssentia USA advances its growth plans.
“We are pleased to welcome Jeffrey to our Board of Directors for PharmaEssentia USA,” said Ko-Chung Lin, Ph.D., founder and chief executive officer. “Jeffrey’s global governance and financial acumen, along with his deep understanding of the East Asian market, will be instrumental as we continue to strengthen our international footprint and deliver innovation to patients worldwide.”
Williams currently serves as a director of UBS SDIC Fund Management Company, UBS Asset Management (China), and Koo Foundation Cancer Center Hospital. He is also a trustee of the CMB Foundation, a trustee of Carleton-Willard Homes, and a council member of the Asian Corporate Governance Association.
He earned his A.B. in East Asian Languages and Civilizations and his M.B.A. from Harvard University.
“Having had the opportunity to work closely with PharmaEssentia’s leadership team in Taiwan, I’ve seen firsthand the company’s dedication to scientific excellence and patient impact,” Williams said. “I’m honored to now extend that partnership to the USA Corporation and look forward to helping guide the company’s continued expansion as it brings innovative therapies to patients around the world.”
